Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer).
Patients with bladder cancer have a substantially increased risk of prostate cancer, compared with that of the general male population, and a diagnosis of concomitant prostate cancer can contribute to inferior outcomes, particularly in patients with muscle-invasive bladder cancer. Here, the authors describe the outcomes of such patients, in addition to the optimal treatment and management strategies and future research needs.
Mathieu Lupien and colleagues analyze data from primary prostate tumors with and without TMPRSS2–ERG (T2E) rearrangements. They find that in T2E tumors, there is a distinct regulatory landscape resulting from the co-option of transcription factors by ERG which causes dependency on NOTCH signaling.
First-line, potent androgen blockade for patients with newly diagnosed, advanced-stage, castration-sensitive prostate cancer is confirmed as an effective strategy by data from the STAMPEDE and LATITUDE trials. Herein, we highlight the benefits, discuss caveats and consider the clinical care implications of these findings.